Keywords: Boehringer Ingelheim, Actilyse, Acute ischemic stroke, UK, NICE

NICE final guidance backs NHS use of Boehringer Ingelheim's Actilyse

Article | 25 September 2012

Print This

In final guidance issued this morning (September 26), UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in